🇺🇸 Efavirenz (EFV) in United States
10 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 10
Most-reported reactions
- Abdominal Distension — 1 report (10%)
- Anorexia — 1 report (10%)
- Aspartate Aminotransferase Increased — 1 report (10%)
- Blood Alkaline Phosphatase Increased — 1 report (10%)
- Blood Bilirubin Increased — 1 report (10%)
- Blood Creatinine Increased — 1 report (10%)
- Blood Potassium Increased — 1 report (10%)
- Blood Sodium Decreased — 1 report (10%)
- Blood Urea Increased — 1 report (10%)
- Cardiomyopathy — 1 report (10%)
Other Infectious Disease / Virology approved in United States
Frequently asked questions
Is Efavirenz (EFV) approved in United States?
Efavirenz (EFV) does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Efavirenz (EFV) in United States?
Janssen-Cilag S.p.A. is the originator. The local marketing authorisation holder may differ — check the official source linked above.